RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+15.53%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.32B
AUM Growth
+$1.32B
(+7.1%)
Cap. Flow
+$23.1M
Cap. Flow
% of AUM
1.76%
Top 10 Holdings %
Top 10 Hldgs %
27.59%
Holding
136
New
16
Increased
50
Reduced
27
Closed
17
Top Buys
Top Sells
| 1 |
AbbVie
ABBV
|
$39M |
| 2 |
STJ
St Jude Medical
STJ
|
$33.4M |
| 3 |
TMH
Team Health Holdings Inc
TMH
|
$17M |
| 4 |
ADPT
Adeptus Health Inc.
ADPT
|
$14.4M |
| 5 |
TRNX
TORNIER N V SHARES (NLD)
TRNX
|
$13.5M |
Sector Composition
| 1 | Healthcare | 77.12% |
| 2 | Financials | 3.37% |
| 3 | Industrials | 0.48% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Cooper Companies
COO
$13.3B
| $5.91M | 0.45% |
44,000
-17,900
| -29% | -$2.4M |
|
77
FibroGen
FGEN
$48.4M
| $5.79M | 0.44% |
190,000
| – | – |
|
|
CO
78
DELISTED
Global Cord Blood Corporation
CO
| $5.61M | 0.42% |
880,000
| – | – |
|
|
FPRX
79
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $5.6M | 0.42% |
135,000
+15,000
| +13% | +$623K |
|
80
Amicus Therapeutics
FOLD
$2.42B
| $5.5M | 0.42% |
566,500
+111,500
| +25% | +$1.08M |
|
|
OTIC
81
DELISTED
Otonomy, Inc.
OTIC
| $5.48M | 0.42% |
197,500
-123,300
| -38% | -$3.42M |
|
|
82
AbbVie
ABBV
$374B
| $5.18M | 0.39% |
87,500
-658,923
| -88% | -$39M |
|
83
Compugen
CGEN
$133M
| $5.14M | 0.39% |
805,000
+280,000
| +53% | +$1.79M |
|
|
AGN.PRA
84
DELISTED
Allergan plc.
AGN.PRA
| $5.14M | 0.39% |
5,000
| – | – |
|
|
NVTA
85
DELISTED
Invitae Corporation
NVTA
| $5.11M | 0.39% |
622,900
+112,900
| +22% | +$927K |
|
86
Ascendis Pharma
ASND
$12.1B
| $4.95M | 0.37% |
270,000
| – | – |
|
|
KITE
87
DELISTED
Kite Pharma, Inc.
KITE
| $4.93M | 0.37% |
80,000
-11,500
| -13% | -$709K |
|
|
GI
88
DELISTED
EndoChoice Holdings, Inc.
GI
| $4.93M | 0.37% |
590,000
+14,000
| +2% | +$117K |
|
89
NovoCure
NVCR
$1.35B
| $4.79M | 0.36% |
+214,316
| New | +$4.79M |
|
|
AIMT
90
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $4.79M | 0.36% |
259,646
+59,646
| +30% | +$1.1M |
|
|
DYAX
91
DELISTED
DYAX CORPORATION
DYAX
| $4.67M | 0.35% |
124,000
+9,500
| +8% | +$357K |
|
|
CLVS
92
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.38M | 0.33% |
+125,000
| New | +$4.38M |
|
93
Perrigo
PRGO
$3.21B
| $4.34M | 0.33% |
+30,000
| New | +$4.34M |
|
94
Cidara Therapeutics
CDTX
$1.61B
| $4.29M | 0.33% |
250,000
-25,000
| -9% | -$429K |
|
95
Sarepta Therapeutics
SRPT
$1.98B
| $4.15M | 0.31% |
+107,500
| New | +$4.15M |
|
|
ATYR
96
aTyr Pharma
ATYR
$560M
| $4.08M | 0.31% |
415,196
+26,200
| +7% | +$258K |
|
97
SCYNEXIS
SCYX
$35.2M
| $3.94M | 0.3% |
635,000
+165,000
| +35% | +$1.02M |
|
|
ALPN
98
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $3.79M | 0.29% |
489,000
| – | – |
|
99
Dynavax Technologies
DVAX
$1.19B
| $3.62M | 0.27% |
150,000
| – | – |
|
100
Rigel Pharmaceuticals
RIGL
$710M
| $3.33M | 0.25% |
+1,100,000
| New | +$3.33M |
|